Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Alkermes reported positive interim results from a long-term extension study of Alixorexton, showing sustained improvements in wakefulness and sleepiness for adults with narcolepsy type 1 and type 2 over approximately nine months. Patient-reported outcomes for cognition and fatigue also showed sustained improvement, while the drug was generally well-tolerated with no serious adverse events reported.
Key figures
- Drug Name
- Alixorexton
- Phase Of Trial
- Phase 2 long-term extension
- Nt1 lte participants
- 78
- Nt1 mean ess week 24
- 7.5
- Nt2 lte participants
- 63
- Nt2 mean ess week 24
- 8.9
- Nt1 mean mwt week 24 minutes
- 29
- Nt2 mean mwt week 24 minutes
- 18
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.